Zobrazeno 1 - 10
of 194
pro vyhledávání: '"David H. Lawson"'
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 1232-1236 (2023)
Programmed death protein-1 (PD-1) checkpoint inhibitors such as pembrolizumab and nivolumab are cornerstones to metastatic melanoma treatment, and they are often considered to be pharmacologically similar and interchangeable when it comes to designin
Externí odkaz:
https://doaj.org/article/81a7ee773b724b4abc580d0c83eb3c38
Autor:
Howa Yeung, Krittin J. Supapannachart, Sandy Francois, Colin H. Adler, Ragini R. Kudchadkar, David H. Lawson, Melinda L. Yushak, Afreen I. Shariff, Suephy C. Chen
Publikováno v:
JID Innovations, Vol 3, Iss 6, Pp 100232- (2023)
Relationships between cutaneous adverse effects (CAEs) and noncutaneous adverse effects (NCAEs) of melanoma immunotherapy may help identify patterns tied to distinct immunologic pathways. The objective of this study was to determine the associations
Externí odkaz:
https://doaj.org/article/23dfe9d3445c4e7cab094e4d698b1611
Autor:
Hannah M. Knochelmann, Michael Brandon Ware, Aditya Rali, Susanne Linderman, Jessica G. Shantha, David H. Lawson, Melinda Yushak, Robert Swerlick, Chrystal M. Paulos, Steven Yeh, Ragini Kudchadkar
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Autoimmune toxicities, while common following treatment with cancer immunotherapies, are not well-characterized in patients treated with BRAF/MEK inhibitors. Emerging data suggest that autoimmune effects may be linked with superior responses to both
Externí odkaz:
https://doaj.org/article/5682dd66a7c94c14983544e2aef025d4
Autor:
Mehmet Asim Bilen, Julie M. Shabto, Dylan J. Martini, Yuan Liu, Colleen Lewis, Hannah Collins, Mehmet Akce, Haydn Kissick, Bradley C. Carthon, Walid L. Shaib, Olatunji B. Alese, Conor E. Steuer, Christina Wu, David H. Lawson, Ragini Kudchadkar, Viraj A. Master, Bassel El-Rayes, Suresh S. Ramalingam, Taofeek K. Owonikoko, R. Donald Harvey
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background Selecting the appropriate patients to receive immunotherapy (IO) remains a challenge due to the lack of optimal biomarkers. The presence of liver metastases has been implicated as a poor prognostic factor in patients with metastat
Externí odkaz:
https://doaj.org/article/3a89538b1b6f4594bd638b17c5ad5f05
Autor:
Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan Curti, Sanjiv S. Agarwala, Bret Taback, Lee Cranmer, Jose Lutzky, Theresa L. Luna, Sandra Aung, David H. Lawson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-8 (2018)
Abstract Background Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in p
Externí odkaz:
https://doaj.org/article/5cdc7070ed8046e696ecf169baa8612b
Autor:
Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie Fecher, Thomas F. Gajewski, Brian Gastman, David H. Lawson, Jose Lutzky, David F. McDermott, Kim A. Margolin, Janice M. Mehnert, Anna C. Pavlick, Jon M. Richards, Krista M. Rubin, William Sharfman, Steven Silverstein, Craig L. Slingluff, Vernon K. Sondak, Ahmad A. Tarhini, John A. Thompson, Walter J. Urba, Richard L. White, Eric D. Whitman, F. Stephen Hodi, Howard L. Kaufman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-23 (2018)
Abstract Background Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination re
Externí odkaz:
https://doaj.org/article/4608673a241f46ca9625955f197bdebe
Autor:
Jonathan S. Zager, Brian R. Gastman, Sancy Leachman, Rene C. Gonzalez, Martin D. Fleming, Laura K. Ferris, Jonhan Ho, Alexander R. Miller, Robert W. Cook, Kyle R. Covington, Kristen Meldi-Plasseraud, Brooke Middlebrook, Lewis H. Kaminester, Anthony Greisinger, Sarah I. Estrada, David M. Pariser, Lee D. Cranmer, Jane L. Messina, John T. Vetto, Jeffrey D. Wayne, Keith A. Delman, David H. Lawson, Pedram Gerami
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background The heterogeneous behavior of patients with melanoma makes prognostication challenging. To address this, a gene expression profile (GEP) test to predict metastatic risk was previously developed. This study evaluates the GEP’s pr
Externí odkaz:
https://doaj.org/article/51ad8d737b2d423ab145b5125b6bb24a
Autor:
Bin Zhang, F. Stephen Hodi, Asim Amin, David H. Lawson, April K.S. Salama, Henry B. Koon, Troy Guthrie, Sajeve S. Thomas, Steven J. O’Day, Montaser F. Shaheen, Stephen Francis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Background Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct mechanisms of action and shared toxicities (e.g., skin, gastrointestinal [GI] and hepatobiliary disorders) that may preclude concomitant admi
Externí odkaz:
https://doaj.org/article/0f77214448854233aa98f583d805a4de
Publikováno v:
Mediators of Inflammation, Vol 2016 (2016)
CD4+ T cell compartments in mouse and man are composed of multiple distinct subsets each possessing unique phenotypic and functional characteristics. IL-17-producing CD4+ T cells (Th17 cells) represent a distinct subset of the CD4+ T cell lineage. Re
Externí odkaz:
https://doaj.org/article/52c4f3bb18194f1c854fee64384e13d9
Autor:
David M. Marcus, Rebecca P. Marcus, Roshan S. Prabhu, Taofeek K. Owonikoko, David H. Lawson, Jeffrey Switchenko, Jonathan J. Beitler
Publikováno v:
Journal of Skin Cancer, Vol 2012 (2012)
Background. While it is established that the incidence of cutaneous melanoma has risen over time in the United States, the incidence trend for mucosal melanoma of the head and neck (MMHN) is unknown. Methods. We used the Surveillance, Epidemiology, a
Externí odkaz:
https://doaj.org/article/141b07f62697443aa0095f346b6bd05c